Patents by Inventor Patricia K. Somers

Patricia K. Somers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and Methods for the Inhibition of the Expression of VCAM-1
    Publication number: 20080214660
    Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
    Type: Application
    Filed: May 15, 2008
    Publication date: September 4, 2008
    Inventors: Russell M. Medford, Patricia K. Somers, Lee K. Hoong, Charles O. Meng
  • Compounds and methods for the inhibition of the expression of VCAM-1
    Patent number: 7189870
    Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: March 13, 2007
    Assignee: AtheroGenic, Inc.
    Inventor: Patricia K. Somers
  • Compounds and methods for treating transplant rejection
    Patent number: 7087645
    Abstract: The use of compounds of the formula and pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are further defined in the application.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: August 8, 2006
    Assignee: AtheroGenics, Inc.
    Inventors: Mitchell Glass, Patricia K. Somers, David B. Edwards
  • Thioketals and thioethers for inhibiting the expression of VCAM-1
    Patent number: 6852878
    Abstract: Thioketals and thioethers are provided that inhibit the expression of VCAM-1, and which can be used in the treatment of VCAM-1 mediated diseases including inflammatory disorders, cardiovascular diseases, occular diseases, autoimmune diseases, neurological disorders, and cancer. The compounds also can be used to treat hyperlipidemia and/or hypercholesterolemia.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: February 8, 2005
    Assignee: Atherogenics, Inc.
    Inventors: Charles Q. Meng, Lee K. Hoong, Patricia K. Somers
  • Compounds and methods for treating transplant rejection
    Publication number: 20040138147
    Abstract: The use of compounds of the formula 1
    Type: Application
    Filed: December 23, 2003
    Publication date: July 15, 2004
    Applicant: Atherogenics, Inc.
    Inventors: Mitchell Glass, Patricia K. Somers, David B. Edwards
  • N-substituted dithiocarbamates for the treatment of biological disorders
    Patent number: 6747061
    Abstract: N-substituted dithiocarbamate esters, pharmaceutical compositions containing them, and methods of treating hyperproliferative disorders such as cancer by administering the N-substituted dithiocarbamate esters.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: June 8, 2004
    Assignee: AtheroGenics, Inc.
    Inventors: Russell M. Medford, Uday Saxena, Lee K. Hoong, Patricia K. Somers
  • Compounds and methods for treating transplant rejection
    Patent number: 6670398
    Abstract: The use of compounds of the formula and pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are further defined in the application.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: December 30, 2003
    Assignee: AtheroGenics, Inc.
    Inventors: David B. Edwards, Patricia K. Somers, Mitchell Glass
  • N-substituted Dithiocarbamates for the Treatment of Biological Disorders
    Publication number: 20030176496
    Abstract: N-substituted dithiocarbamate esters in which the amine function bears a hydrogen are provides, as are methods for using the compounds in the treatment of cellular hyperproliferation and VCAM-1 mediated disease. Particularly provided is a method of treating a hyperproliferative disorder such as cancer comprising administering an antiproliferative agent in combination with a potentiating effective amount of a N-substituted dithiocarbamate ester. Also provided are methods of using the compounds in the treatment of VCAM-1 mediated diseases such as inflammation and carrdiovascular disease.
    Type: Application
    Filed: March 21, 2001
    Publication date: September 18, 2003
    Applicant: AtheroGenics, Inc.
    Inventors: Russell M. Medford , Saxena Uday , Lee K. Hoong , Patricia K. Somers
  • Compounds and methods for the inhibition of the expression of VCAM-1
    Patent number: 6617352
    Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
    Type: Grant
    Filed: January 30, 2002
    Date of Patent: September 9, 2003
    Assignee: Atherogenics, Inc.
    Inventor: Patricia K. Somers
  • Compounds and methods of treating transplant rejection
    Publication number: 20030153536
    Abstract: The use of compounds of the formula 1
    Type: Application
    Filed: October 25, 2002
    Publication date: August 14, 2003
    Inventors: Mitchell Glass, Patricia K. Somers, David B. Edwards
  • Compounds and methods for the inhibition of the expression of VCAM-1
    Patent number: 6548699
    Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
    Type: Grant
    Filed: August 6, 1999
    Date of Patent: April 15, 2003
    Assignee: Atherogenics, Inc.
    Inventor: Patricia K. Somers
  • Compounds and methods for the inhibition of the expression of VCAM-1
    Publication number: 20020177717
    Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
    Type: Application
    Filed: January 30, 2002
    Publication date: November 28, 2002
    Inventor: Patricia K. Somers
  • Compounds and methods for treating transplant rejection
    Publication number: 20020156022
    Abstract: The use of compounds of the formula 1
    Type: Application
    Filed: October 25, 2001
    Publication date: October 24, 2002
    Inventors: David B. Edwards, Patricia K. Somers, Mitchell Glass
  • Thioketals and thioethers for inhibiting the expression of VCAM-1
    Publication number: 20020016300
    Abstract: Thioketals and thioethers are provided that inhibit the expression of VCAM-1, and which can be used in the treatment of VCAM-1 mediated diseases including inflammatory disorders, cardiovascular diseases, occular diseases, autoimmune diseases, neurological disorders, and cancer. The compounds also can be used to treat hyperlipidemia and/or hypercholesterolemia.
    Type: Application
    Filed: March 21, 2001
    Publication date: February 7, 2002
    Inventors: Charles Q. Meng, Lee K. Hoong, Patricia K. Somers
  • Compounds and methods for the inhibition of the expression of VCAM-1
    Patent number: 6147250
    Abstract: This invention is in the area of methods and compositions for the inhibition of the expression of VCAM-1 and, in particular, for the treatment of diseases mediated by VCAM-1, including cardiovascular and inflammatory diseases.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: November 14, 2000
    Assignee: AtheroGenics, Inc.
    Inventor: Patricia K. Somers
  • Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
    Patent number: 6121319
    Abstract: This invention is a method and composition for the inhibition of VCAM-1, and in particular for the treatment of cardiovascular or inflammatory disease, including atherosclerosis, that includes the administration of an effective amount of an ester of probucol.
    Type: Grant
    Filed: May 14, 1998
    Date of Patent: September 19, 2000
    Assignee: AtheroGenics, Inc.
    Inventor: Patricia K. Somers